Addendum
Dupilumab (COPD) - Addendum to Project A24-79
Report documents
-
Addendum
Dupilumab (COPD) - Addendum to Project A24-79
Dossier assessment
Add-on maintenance treatment of adult patients with uncontrolled COPD characterized by raised blood eosinophils on a combination of an inhaled corticosteroid, a long-acting beta-2 agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if an inhaled corticosteroid is not appropriate
After addendum now:
- Patients who are not eligible for treatment with roflumilast: hint of minor added benefit
- Patients who are eligible for treatment with roflumilast: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2025-02-06 A G-BA decision was published.
Project details
- Project no.
- A24-118
- Commission
- Commission awarded on 10.12.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-118_en
Connected Projects
-
Dossier assessment
Dupilumab (COPD) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed